Loading…
Loading…
TMDX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for TMDX and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for TMDX and 80,000+ other tickers.
See exactly how TMDX's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TMDX and 80,000+ other tickers.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized…
ANDOVER, Mass., Oct. 22, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2026 after market close on Thursday, November 5, 2026.
On October 21, 2026, TransMedics Group Inc (TMDX) shares fell by 3.1%, bringing the current price to $72.40. This decline is notable within a 52-week range of $
TransMedics Group (NASDAQ: TMDX - Get Free Report) and iRhythm Technologies (NASDAQ: IRTC - Get Free Report) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability. Institutional and Insider Ownership 99.7% of TransMedics
On October 01, 2026, TransMedics Group Inc (TMDX) shares fell 5.8%, closing at $78.64. The stock's performance over the past year has been challenging, with a 5
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireNEW YORK, Sept. 26, 2026Shareholders are encouraged to contact the